USE OF BACTERIAL LYSATE IN COMPLEX TREATMENT OF ACUTE BRONCHITIS COMBINED WITH EUTHYROID SICK SYNDROME IN PRESCHOOLERS

Keywords: acute bronchitis, children, euthyroid sick syndrome, humoral immunity, immunoglobulin A, immunoglobulin M, immunoglobulin G, immunomodulator, bacterial lysate

Abstract

Objective. This study's objective was to determine bacterial lysate's effect on the state of humoral immunity (IgA, IgM, IgG) in preschool children with acute bronchitis in combination with euthyroid sick syndrome.

Materials and methods. We examined 135 children of preschool age (3 to 6 years) with acute bronchitis (main group) and 28 healthy children (control group). Group Ia included 45 children with acute bronchitis who were treated according to the standard scheme. Preschoolers with acute bronchitis in Group Ib (47 patients) additionally received bacterial lysate. Group IIa included 21 children with acute bronchitis and euthyroid sick syndrome (ESS) manifestations who received standard therapy. Group IIb consisted of 22 patients with acute bronchitis and ESS who received standard therapy and were additionally given an immunomodulator.

The bacterial lysate consisted of Staphylococcus aureus 6×109 colony-forming units (CFU), Streptococcus pyogenes 6×109 CFU, Streptococcus viridans 6×109 CFU, Klebsiella pneumoniae 6×109 CFU, Klebsiella ozaenae 6×109 CFU, Haemophilus influenzae B 6×109 CFU, Neisseria catarrhalis 6×109 CFU, Streptococcus pneumoniae 6×109 CFU (the latter included the following types in amount of 1×109 CFU each: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24). The effectiveness of bacterial lysate in children with acute bronchitis and with or without ESS was determined by comparing the humoral immunity parameters (IgA, IgM, IgG) in the acute period (1 to 2 days after the onset) and convalescence period (7 to 10 days after the onset).

Levels of immunoglobulins (IgA, IgM, and IgG) were measured by solid-phase enzyme-linked immunosorbent assay.  All results were statistically processed using the SPSS 26 software.

Results. No statistically significant difference was found between the values of immunoglobulins A, M, and G in children with acute bronchitis and with or without ESS manifestations in the acute period of the disease. At the same time, the above parameters were significantly higher than the corresponding values in the control group.

A statistically significant difference was observed in the humoral immunity parameters of patients who were given the bacterial lysate vs. patients who were not.

In children who were additionally given the bacterial lysate, IgA levels practically equaled the levels of the control group in the convalescence period. The serum levels of IgM and IgG in children who additionally received the immunomodulator tended to approach the values of the control group.

Conclusions. The use of bacterial lysate positively affected the restoration of humoral homeostasis, especially on the level of immunoglobulin A, in children with acute bronchitis and with or without the euthyroid sick syndrome. The bacterial lysate demonstrated high efficiency against this disease in this group of patients.

Author Biography

Anastasiia Havrylenko, Department of Pediatrics, Medical Institute, Sumy State University, Sumy, Ukraine

Medical Institute, Sumy State University, 31 Sanatorna st., 40018 Sumy, Ukraine; e‑mail: dr.nania@gmail.com, tel: +380663109979

References

1. Lezhenko HO, Abaturov OI, Pashkova OI. [The role of endogenous antimicrobial peptides in bacterial colonization of the nasopharynx in children with retronasal amygdala hyperplasia]. Zdorov'e rebenka. 2016;6:74-81.
2. Majdannik VG, Emchinskaya EA. Klinicheskie rekomendacii po diagnostike i lecheniyu ostrykh bronkhitov u detej s pozicii dokazatel'noj mediciny. [Clinical recommendations for the diagnosis and treatment of acute bronchitis in children from the standpoint of evidence-based medicine]. Kiev: NMU im. A.A. Bogomol'ca, 2014. 56 p.
3. Maidannyk VH, Falalieieva TM, Molochek NV, Romanenko SI. [Clinical guidelines for the treatment and prevention of complications of acute respiratory infections in children]. Mizhnarodnyi zhurnal pediatrii, akusherstva ta hinekolohii. 2019;13(3):56-99.
4. Tokarieva NM. Osoblyvosti mukozalnoho zakhystu pry hostrykh bronkhitakh u ditei. [Features of mucosal protection in acute bronchitis in children]. Retrieved from: https://ipag-kiev.org.ua/wp-content/uploads/2019/12/dis_tok.pdf
5. Chenchak VA. [Features of the action of thyroxine on the immune system]. Mezhdunarodnyj studencheskij nauchnyj vestnik. 2017;3. Retrieved from: https://www.eduherald.ru/ru/article/view?id=17190
6. Kusel'man AI, Solov'eva IL, Cherdancev AP. Gerpesvirusnye infekcii u detej: rukovodstvo dlya vrachej. [Herpesvirus infections in children: a guide for doctors]. Ul'yanovsk: ULGU, 2017. 280 р.
7. Sirotina OB. [Thyroid health in children with thymomegaly]. Vestnik perinatologii i pediatrii. 2010;4:66-69.
8. Ganesan K, Wadud K. Euthyroid Sick Syndrome. StatPearls Publishing, 2021.
9. Hershman JM. Euthyroid Sick Syndrome. MSD Manual. Professional Version. Retrieved from: https://www.msdmanuals.com/professional/endocrine-and-metabolic-disorders/thyroid-disorders/euthyroid-sick-syndrome
10. Lee S, Farwell AP. Euthyroid Sick Syndrome. Compr Physiol. 2016;6(2):1071.
11. Luca R De, Davis PJ, Lin H-Y, et al. Thyroid Hormones Interaction With Immune Response, Inflammation and Non-thyroidal Illness Syndrome. Front Cell Dev Biol. 2021;8:614030. doi: 10.3389/fcell.2020.614030
12. Kozlov IG, Andronova TM. [Medicinal effects through innate immune receptors]. Allergology and Immunology. 2013;14(4):254-259.
13. Kazmirchuk VE, Koval'chuk LV, Mal'cev DV. Clinical immunology and allergology with age-related features. Medicine, 2012. 520 p.
14. Pinegin BV, Pashchenkov MV. [Muramylpeptide immunostimulants in the treatment and prevention of infectious and inflammatory processes]. Immunology. 2019;40(3):65-71.
15. Feshchenko YI, Yashina LA, Ishchuk SG, Matvienko YA. [Possibilities of using the immunostimulating drug licopid in pulmonology]. Asthma and allergy. 2012;1:61-65.
16. Karaulov AV. [Immunomodulators in the prevention and treatment of respiratory infections in children]. Pharmateka. 2017;1. Retrieved from: https://pharmateca.ru/ru/archive/article/8334
17. Koloskova OK. [Clinical and Inflammometric Indices of Respibron Efficacy in Multimodal Therapy of Febrile Seizures in Bronchial Asthma in Children of Preschool Age]. Clinical pediatrics. 2012;2(37):37-41.
18. Braido F, et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: A multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: Advanced Immunological Approach in COPD Exacerbation). Pulm Pharmacol Ther. 2015;33:75-80. doi: 10.1016/j.pupt.2015.03.006
19. Abrams EM, Raissy HH. Emerging Therapies in the Treatment of Early Childhood Wheeze. Pediatr Allergy Immunol Pulmonol. 2019;32(2):78-80. doi: 10.1089/ped.2019.1043
20. Emeryk A, Bartkowiak-Emeryk M, Raus Z, Braido F, Ferlazzo G, Melioli G. Mechanical bacterial lysate administration prevents exacerbation in allergic asthmatic children-The EOLIA study. Pediatr. Allergy Immunol. 2018;29(4):394-401. doi: 10.1111/pai.12894
21. Babinec OM. [Correction of experimental dysbiosis with probiotic preparations immobilized on enterosorbents after their low-temperature storage]. Bulletin of problems of biology and medicine. 2012;4;1(96):72-78.
22. Zielnik-Jurkiewicz В, Jurkiewicz D. Bacterial lysates in the prevention of respiratory tract infections. Otolaryngol. Pol. 2018;31;72(5):1-8. doi: 10.5604/01.3001.0012.7216
23. Pysanko VM. [Efficacy of respibron for the immunoprophylaxis of chronic and recurrent rhinosinusitis in children]. Sovremennaya pediatriya. 2017;4(84):22¬28. doi: 10.15574/SP.2017.84.22
24. Vdovichenko N, Tupotilov O, Bojko A, Kolyada O. [Correction of humoral immunity disorders in patients with chronic tonsillitis and diabetes mellitus]. AMI. 2015;2:215-219. Retrieved from: http://journals.uran.ua/ami/article/view/193028
25. Geertje M, Żółkiewicz J, Konrad PS, Ruszczyński M, Rudi WH, Braunstahl GJ, Feleszko W, Gerdien. A. Bacterial lysate therapy for the prevention of wheezing episodes and asthma exacerbations: a systematic review and meta-analysis. European Respiratory Review. 2020;29:190175. doi: 10.1183/16000617.0175-2019
26. Esposito S, Soto-Martinez ME, Feleszko W, Jones MH, Shen KL, Schaad UB. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Current Opinion in Allergy and Clinical Immunology. 2018;18(3):198-209. doi: 10.1097/ACI.0000000000000433
27. Zielnik-Jurkiewicz B, Jurkiewicz D. Bacterial lysates in the prevention of respiratory tract infections. Otolaryngol Pol. 2018;72(5):1-8. doi: 10.5604/01.3001.0012.7216
Published
2022-09-30
How to Cite
Anastasiia Havrylenko. (2022). USE OF BACTERIAL LYSATE IN COMPLEX TREATMENT OF ACUTE BRONCHITIS COMBINED WITH EUTHYROID SICK SYNDROME IN PRESCHOOLERS. Eastern Ukrainian Medical Journal, 10(3), 205-213. https://doi.org/10.21272/eumj.2022;10(3):205-213